Severity of the toxicity associated with combinations that include didanosine plus stavudine in HIV-infected experienced patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 5, 2006, Pages 556-559

  Hernández, Beatriz ^a   Moreno, Santiago ^a   Pérez Elías, María J ^a   Casado, José L ^a   Dronda, Fernando ^a   Moreno, Ana ^a   Antela, Antonio ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Didanosine; Salvage; Stavudine; Toxicity

Indexed keywords

DIDANOSINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; DIARRHEA; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATALITY; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERLACTATEMIA; HYPERTRIGLYCERIDEMIA; KAPLAN MEIER METHOD; LABORATORY TEST; LACTIC ACIDOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; TREATMENT FAILURE; VOMITING; WEIGHT REDUCTION;

ADULT; COHORT STUDIES; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; STAVUDINE;

EID: 33845361890     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000245881.20768.95     Document Type: Review

References (16)

1. Bristol-Myers Squibb Company. Important drug warning - Zerit and Videx. 2001. Available at: http://www.fda.gov/medwatch/SAFETY/2001/ Zerit&Videx_letter.htm. Accessed April 19, 2006.
2. Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2005. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed August 31, 2005.
3. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251-265.
4. Iribarren JA, Labarga P, Rubio R, et al. Grupo de Estudio de Sida; Consejo Asesor Clinico del Plan Nacional sobre el Sida del Ministerio de Sanidad y Consumo. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004). Enferm Infecc Microbiol Clin. 2004;22:564-642.
5. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
6. Whitcomb JM, Parkin NT, Chappey C, et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis. 2003;188:992-1000.
7. Eron JJ Jr, Murphy RL, Peterson D, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS. 2000;14:1601-1610.
8. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17:987-999.
9. French M, Amin J, Roth N, et al, for the OzCombo 2 Investigators. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: the OzCombo 2 study. HIV Clin Trials. 2002;3:177-185.
10. Nuñez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials. 2002;3:186-194.
11. Saag MS, Cahn P, Raffi F, et al, for the FTC-301A Study Team. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA. 2004;292:180-189.
12. Robbins GK, De Gruttola V, Shafer RW, et al, for the AIDS Clinical Trials Group 384 Team. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293-2303.
13. Molina JM, Marcelin AG, Pavie J, et al, for the AI454-176 JAGUAR Study Team. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis. 2005;191:840-847.
14. Cozzi-Lepri A, Ruiz L, Loveday C, et al. for the EuroSIDA Study Group. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther. 2005;10:791-802.
15. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med. 1997;126:355-363.
16. Lambert JS, Seidlin M, Reichman RC, et al. 2′,3′- Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990;322:1333-1340.